P21 (P021)

Think of it as a blueprint for a promising bridge that has only ever been built and stress-tested as a scale model. The model behaves beautifully in the lab. No full-size bridge has been built and nobody has driven across one. Buying 'P21' today is like buying a ticket to cross a bridge that exists only as a model.

Engineered from the biologically active region of ciliary neurotrophic factor (CNTF), with an adamantane modification for stability and brain penetration. It enhances hippocampal (dentate gyrus) neurogenesis and synaptic plasticity by antagonising inhibitory LIF/CNTF-family signalling and increasing BDNF expression. Elevated BDNF reduces GSK-3-beta activity, lowering abnormal tau hyperphosphorylation. In animal models this combination is associated with reduced tau and amyloid pathology and improved learning and memory.

Research contexts. Not proven uses, and not recommendations.

None. There are no published or registered human clinical trials of P21/P021 at any phase, no human pharmacokinetic or safety data, and no regulatory approval in the UK, EU or US. The entire evidence base is preclinical and dominated by a single research group. Any claim of cognitive benefit in humans is unsupported.

• !No human data: efficacy, safety, tolerability and side-effect profile in people are entirely unknown.
• !Evidence is concentrated in one research group. Many neurotrophic Alzheimer's candidates have failed when moved from mice to humans.
• !Sold as an unlicensed 'research chemical' marked 'not for human consumption', with no pharmaceutical-grade manufacturing and no purity, sterility or content guarantees.
• !Modulating neurotrophic and neurogenic pathways (BDNF, CNTF-family signalling) is biologically powerful and unproven in humans. Unknown risks surround aberrant cell proliferation or off-target neural effects.
• !Marketing materials frequently overstate the rodent findings as if they applied to human cognition or Alzheimer's treatment.

Not a licensed medicine in the UK. The MHRA has approved no P21/P021 product, and there is no known authorised UK clinical trial. It is an unlicensed substance sold by research-chemical vendors labelled 'for research use only / not for human consumption'. Supplying or selling it for human use would engage the Human Medicines Regulations 2012 as an unlicensed medicinal product. There is no legitimate prescription route; any human use is unapproved and unregulated.

1. 01
   Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease — Kazim SF, Blanchard J, Dai C-L, Tung Y-C, LaFerla FM, Iqbal I-G, Iqbal K, Neurobiology of Disease (2014)

   Landmark preclinical study: chronic oral P021 in 3xTg-AD mice rescued memory and neurogenesis and attenuated tau (and more modestly amyloid) pathology.

2. 02
   Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound — Baazaoui N, Iqbal K, Alzheimer's Research & Therapy (2017)

   Preclinical demonstration that P021 prevents dendritic/synaptic deficits and cognitive impairment in a mouse model.

3. 03
   Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease — Kazim SF, Iqbal K, Molecular Neurodegeneration (2016)

   Review situating P021 among CNTF/neurotrophic mimetics; describes LIF antagonism and the BDNF-mediated mechanism.

4. 04
   Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound — Baazaoui N, Iqbal K, Biomolecules (2022)

   Recent review reiterating the preclinical P021 rationale; presents only animal data and no human evidence.

5. 05
   P021 - Cognitive Vitality Report — Alzheimer's Drug Discovery Foundation (ADDF), AlzDiscovery.org (Cognitive Vitality) (2025)

   Independent review (last updated 2025) confirming P021 has not been tested in human clinical trials.